Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference


Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 8:00 a.m. ET in New York, NY.

A live webcast of the presentation can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. For more information, please visit www.sagerx.com.


These press releases may also interest you

at 18:30
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four...

at 18:16
GLOBE LIFE INC. ANNOUNCES FIRST QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 17:56
Canadian Cancer Society commends tobacco tax and e-cigarette tax increases in federal budget
The Canadian Cancer Society commends the increases in taxes on tobacco and e-cigarettes in today's federal budget.  The budget increases tobacco taxes by $4.00 per carton of 200 cigarettes effective at midnight, and increases e-cigarette taxes by 12%...

at 17:45
Alvotech and Teva Announce U.S. FDA Approval of SELARSDItm (ustekinumab-aekn), biosimilar to StelaraŽ (ustekinumab)
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to...

at 17:31
Global Dental Lasers Market to Witness Upsurge in Growth at a CAGR of ~5% by 2030 | DelveInsight
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...

at 17:26
AMGEN TO PRESENT TEZSPIREŽ PHASE 2A COPD DATA AT ATS 2024
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIREŽ (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...

More news about Health...


News published on and distributed by: